OASIS Mailing List ArchivesView the OASIS mailing list archive below
or browse/search using MarkMail.

 


Help: OASIS Mailing Lists Help | MarkMail Help

dita-busdocs message

[Date Prev] | [Thread Prev] | [Thread Next] | [Date Next] -- [Date Index] | [Thread Index] | [List Home]


Subject: RE: [dita-busdocs] Question from DITA Pharma SC: any good practicefor topic-based review?


Hi Josef,

 

I also do not recall addressing topic-based review, as we have thought in terms of aggregated topic authoring and review. There is an interesting subject that I hope we can explore sometime regarding the use of multiple maps to aggregate topics for review based on metadata.

 

Regarding topic relationships, I have been thinking about this recently in terms of pharmaceutical submission content, particularly in the area of CMC Module 2 and 3 summary/detail and document automation. I suspect that this would only be addressed in broad concept by Rob’s model, as the actual specializations that would deliver this type of relationship would belong to a domain such as the Pharma SC.

 

We should discuss this sometime at our meeting—would be interesting to vet whether there are similar use cases in other industries. If so, Rob might think about whether this creates another dimension in his model, which could in some way formalize the relationship of detail and summary versions of siblings within an information model. Challenging, but it sounds like the type of puzzle that might interest Rob.

 

Regards,

 

Michael

 

From: josef.pellizzari@novartis.com [mailto:josef.pellizzari@novartis.com]
Sent: Monday, November 29, 2010 9:31 AM
To: dita-busdocs@lists.oasis-open.org
Subject: [dita-busdocs] Question from DITA Pharma SC: any good practice for topic-based review?

 


Hi all,

In the last DITA Pharma SC a question popped up around reviewing: is there any good practice or process for topic-based review? As "reviewing" is associated with "enterprise" the Pharma SC was looking at us or the Adoption SC for answers.

I remember vaguely that we discussed reviewing as one potential business case for an aggregated document, but as far as I remember we never spent any time on topic-based reviewing for  business documents. Anything to carry back to the Pharma colleagues?

A second question was around relationships of topics. In Pharma documents (and Pharma SC thinks also in business documents) we often have the same information in different forms for different audiences or different parts of the documumentation (summary vs. full detail, lay language vs. expert language, etc). I cannot recall that we spent any time on this, or that Rob's model would take this into account. Right?

Best regards,

Josef

Josef Pellizzari
Novartis Pharma AG

CHBS, WSJ-154.2.03C.12
Novartis Pharma AG
Forum 1
Novartis Campus
CH-4056 Basel
Switzerland
Phone: +41 61 3248825
Fax: +41 61 6961312
Email :
josef.pellizzari@novartis.com

 



[Date Prev] | [Thread Prev] | [Thread Next] | [Date Next] -- [Date Index] | [Thread Index] | [List Home]